Jiang Liyang, Liu Na, Zhao Fabao, Huang Boshi, Kang Dongwei, Zhan Peng, Liu Xinyong
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Acta Pharm Sin B. 2024 May;14(5):1987-2005. doi: 10.1016/j.apsb.2024.01.004. Epub 2024 Jan 10.
The -methyl-d-aspartate (NMDA) receptors, which belong to the ionotropic Glutamate receptors, constitute a family of ligand-gated ion channels. Within the various subtypes of NMDA receptors, the GluN1/2A subtype plays a significant role in central nervous system (CNS) disorders. The present article aims to provide a comprehensive review of ligands targeting GluN2A-containing NMDA receptors, encompassing negative allosteric modulators (NAMs), positive allosteric modulators (PAMs) and competitive antagonists. Moreover, the ligands' structure-activity relationships (SARs) and the binding models of representative ligands are also discussed, providing valuable insights for the clinical rational design of effective drugs targeting CNS diseases.
N-甲基-D-天冬氨酸(NMDA)受体属于离子型谷氨酸受体,构成了一个配体门控离子通道家族。在NMDA受体的各种亚型中,GluN1/2A亚型在中枢神经系统(CNS)疾病中发挥着重要作用。本文旨在全面综述靶向含GluN2A的NMDA受体的配体,包括负变构调节剂(NAMs)、正变构调节剂(PAMs)和竞争性拮抗剂。此外,还讨论了这些配体的构效关系(SARs)以及代表性配体的结合模型,为临床合理设计针对CNS疾病的有效药物提供了有价值的见解。